Business
Second Study Affirms Superiority of iMDx GraftAssure Assay’s Proprietary dd-cfDNA Combination Model Score
New data supports GraftAssure commercialization effortsMulti-center study featured 249 biopsy-matched patientsProprietary “Combination Model” score outperformed percentage-only measures of dd-cfDNAReinforces data presented at World Transplant Congress in 2025 NASHVILLE, Tenn., March 13, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc. (Nasdaq: IMDX) (“iMDx”) today highlighted the publication of a new peer-reviewed study demonstrating the potential superiority of the company’s flagship
About this update from Insight Molecular Diagnostics Inc.
[{"type":"image","alt":"Insight Molecular Diagnostics Inc.","displaySize":"","headline":null,"caption":"Insight Molecular Diagnostics Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":114,"url":"https://media.zenfs.com/en/globenewswire.com/0d7abfd3cc0e9f19d3f8615dce794ac4"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/a9omE9cBUejfoy9a_jJadQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2MDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/0d7abfd3cc0e9f19d3f8615dce794ac4","width":300,"height":114}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"New data supports GraftAssure commercialization efforts","length":55,"tagName":"p"}]},{"val":[{"type":"text","content":"Multi-center study featured 249 biopsy-matched patients","length":55,"tagName":"p"}]},{"val":[{"type":"text","content":"Proprietary “Combination Model” score outperformed percentage-only measures of dd-cfDNA","length":87,"tagName":"p"}]},{"val":[{"type":"text","content":"Reinforces data presented at World Transplant Congress in 2025","length":62,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":259,"olType":false},{"type":"text","content":"NASHVILLE, Tenn., March 13, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc. (Nasdaq: IMDX) (“iMDx”) today highlighted the publication of a new peer-reviewed study demonstrating the potential superiority of the company’s flagship GraftAssureTM assay technology.","length":272,"tagName":"p"},{"type":"text","content":"The study, published in Transplant International, and titled “Donor-Derived Cell-Free DNA as a Non-Invasive Readout of Activity Across the Rejection Continuum,” was conducted by investigators from Heidelberg University Hospital and Charité – Universitätsmedizin Berlin and included iMDx scientist authors.","length":305,"tagName":"p"},{"type":"text","content":"This new study, combined with data presented at World Transplant Congress in 2025, point to growing clinical differentiation and marketability of the GraftAssure technology and support iMDx’s strategic vision. Beginning in 2026, iMDx seeks to deliver the industry-leading molecular diagnostic test kit for clinical use that expands and improves access to organ health testing for kidney transplant patients. The company expects that enabling localized testing will deliver new value in the roughly $2 billion-plus...